MX2023002246A - Sistema sintetico de crispr-cas en miniatura (casmini) para modificacion de genomas de eucariotas. - Google Patents

Sistema sintetico de crispr-cas en miniatura (casmini) para modificacion de genomas de eucariotas.

Info

Publication number
MX2023002246A
MX2023002246A MX2023002246A MX2023002246A MX2023002246A MX 2023002246 A MX2023002246 A MX 2023002246A MX 2023002246 A MX2023002246 A MX 2023002246A MX 2023002246 A MX2023002246 A MX 2023002246A MX 2023002246 A MX2023002246 A MX 2023002246A
Authority
MX
Mexico
Prior art keywords
cas
rna molecules
casmini
cas proteins
genome engineering
Prior art date
Application number
MX2023002246A
Other languages
English (en)
Inventor
Lei S Qi
Xiaoshu Xu
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2023002246A publication Critical patent/MX2023002246A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Tea And Coffee (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

En la presente se proporcionan proteínas Cas y moléculas de ARN guía modificadas para mostrar una actividad incrementada en células eucariotas. Las proteínas Cas y las moléculas de ARN guía, proporcionadas, son particularmente útiles para aplicaciones donde resulta ventajosa la modulación de ácidos nucleicos eucarióticos con moléculas relativamente pequeñas. También se proporcionan ácidos nucleicos y vectores que codifican para las proteínas Cas y las moléculas de ARN guía, divulgadas, composiciones farmacéuticas que incluyen las proteínas Cas y las moléculas de ARN guía, y métodos para utilizar los materiales divulgados.
MX2023002246A 2020-09-01 2021-08-31 Sistema sintetico de crispr-cas en miniatura (casmini) para modificacion de genomas de eucariotas. MX2023002246A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073377P 2020-09-01 2020-09-01
US202163191611P 2021-05-21 2021-05-21
PCT/US2021/048362 WO2022051250A1 (en) 2020-09-01 2021-08-31 Synthetic miniature crispr-cas (casmini) system for eukaryotic genome engineering

Publications (1)

Publication Number Publication Date
MX2023002246A true MX2023002246A (es) 2023-05-09

Family

ID=80492161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002246A MX2023002246A (es) 2020-09-01 2021-08-31 Sistema sintetico de crispr-cas en miniatura (casmini) para modificacion de genomas de eucariotas.

Country Status (12)

Country Link
US (1) US20230340439A1 (es)
EP (1) EP4208545A1 (es)
JP (1) JP2023538964A (es)
KR (1) KR20230076820A (es)
CN (1) CN116438313A (es)
AU (1) AU2021337539A1 (es)
BR (1) BR112023003784A2 (es)
CA (1) CA3192654A1 (es)
GB (1) GB2615903A (es)
IL (1) IL301017A (es)
MX (1) MX2023002246A (es)
WO (1) WO2022051250A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3223009A1 (en) * 2021-06-17 2022-12-22 Kaiyi JIANG Systems, methods, and compositions comprising miniature crispr nucleases for gene editing and programmable gene activation and inhibition
WO2023168242A1 (en) * 2022-03-01 2023-09-07 Epicrispr Biotechnologies, Inc. Engineered nucleases, compositions, and methods of use thereof
WO2023173110A1 (en) * 2022-03-11 2023-09-14 Epicrispr Biotechnologies, Inc. Compositions, systems, and methods for treating familial hypercholesterolemia by targeting pcsk9
WO2023240137A1 (en) * 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4219699A1 (en) * 2013-12-12 2023-08-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
CN111757889B (zh) * 2018-10-29 2021-05-25 中国农业大学 新型CRISPR/Cas12f酶和系统
US20200199555A1 (en) * 2018-12-05 2020-06-25 The Broad Institute, Inc. Cas proteins with reduced immunogenicity and methods of screening thereof

Also Published As

Publication number Publication date
AU2021337539A1 (en) 2023-05-04
GB2615903A (en) 2023-08-23
IL301017A (en) 2023-05-01
JP2023538964A (ja) 2023-09-12
EP4208545A1 (en) 2023-07-12
CN116438313A (zh) 2023-07-14
BR112023003784A2 (pt) 2023-03-28
KR20230076820A (ko) 2023-05-31
CA3192654A1 (en) 2022-03-10
WO2022051250A1 (en) 2022-03-10
GB202304773D0 (en) 2023-05-17
US20230340439A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
MX2023002246A (es) Sistema sintetico de crispr-cas en miniatura (casmini) para modificacion de genomas de eucariotas.
WO2021158921A3 (en) Adenine base editors and uses thereof
PH12021550904A1 (en) Novel crispr/cas12f enzyme and system
CN103233028B (zh) 一种无物种限制无生物安全性问题的真核生物基因打靶方法及螺旋结构dna序列
PH12017502281A1 (en) Thermostable cas9 nucleases
BR112019006388A2 (pt) enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas
EA201991442A1 (ru) ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
GB2569733A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
MX2022011460A (es) Composiciones y métodos para el direccionamiento de c9orf72.
EP1025217A4 (en) RECOMBINATORY CLONING USING NUCLEIC ACIDS HAVING RECOMBINATION SITES
BR0010725A (pt) Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
WO2005014796A3 (en) Methods and compositions for seamless cloning of nucleic acid molecules
DE60330044D1 (de) Il-21-produktion in prokaryontischen wirten
ZA202207849B (en) Regulatory nucleic acid sequences
EA202190454A1 (ru) Новый crispr-ассоциированный белок и его применение
Cheng et al. A switch in a substrate tunnel for directing regioselectivity of nitrile hydratases towards α, ω-dinitriles
WO2003076561A3 (en) Recombinase fusion protein with enhanced cellular uptake
Chen et al. Aptazyme-mediated direct modulation of post-transcriptional sgRNA level for conditional genome editing and gene expression
Boldinova et al. Optimization of the expression, purification and polymerase activity reaction conditions of recombinant human PrimPol
Ros et al. Learning from nature to expand the genetic code
MX2023005496A (es) Meganucleasas manipuladas genéticamente que tienen especifidad para secuencias de reconocimiento en el gen de la distrofina.
Wu et al. A chemoenzymatic cascade with the potential to feed the world and allow humans to live in space
WO2023114473A3 (en) Recombinant reverse transcriptase variants for improved performance
WO2022171780A3 (en) Alpha-amylase variants
ATE552334T1 (de) Serumfreies medium zur herstellung von retroviralen vektoren